id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-E-2326-0008,FDA,FDA-2014-E-2326,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2019-03-08T05:00:00Z,2019,3,2019-03-08T05:00:00Z,,2019-03-08T13:08:04Z,,0,0,0900006483acbdb5
FDA-2014-E-2326-0007,FDA,FDA-2014-E-2326,"Determination of Regulatory Review Period for Purposes of Patent
Extension; FETZIMA",Notice,Determinations,2018-02-15T05:00:00Z,2018,2,2018-02-15T05:00:00Z,2018-04-17T03:59:59Z,2018-02-15T16:10:28Z,2018-03129,0,0,0900006482f34642
FDA-2014-E-2326-0006,FDA,FDA-2014-E-2326,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2017-07-26T04:00:00Z,2017,7,2017-07-26T04:00:00Z,,2017-07-26T14:03:31Z,,0,0,090000648296c91e
FDA-2014-E-2326-0005,FDA,FDA-2014-E-2326,Regulatory Review Letter,Other,Letter(s),2017-05-12T04:00:00Z,2017,5,2017-05-12T04:00:00Z,,2017-05-12T22:09:48Z,,0,0,09000064825aff37
FDA-2014-E-2326-0004,FDA,FDA-2014-E-2326,Letter from U.S. Patent and Trademark Office to FDA,Other,Letter(s),2016-12-23T05:00:00Z,2016,12,2016-12-23T05:00:00Z,,2016-12-23T16:36:59Z,,0,0,090000648243459d
FDA-2014-E-2326-0003,FDA,FDA-2014-E-2326,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-11-03T05:00:00Z,2015,11,2015-11-03T05:00:00Z,,2015-11-03T19:51:51Z,,0,0,0900006481d09b01
FDA-2014-E-2326-0001,FDA,FDA-2014-E-2326,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2015-01-07T05:00:00Z,2015,1,2015-01-07T05:00:00Z,,2015-01-07T22:33:59Z,,0,0,09000064819ac236
FDA-2014-E-2326-0002,FDA,FDA-2014-E-2326,"Patent Term Extension Application from Finnegan, Henderson, Farabow, Garrett and Dunner, LLP on Behalf of Pierre Fabre Medicament",Other,Application,2015-01-07T05:00:00Z,2015,1,2015-01-07T05:00:00Z,,2015-01-07T22:34:05Z,,0,0,09000064819ac238